Free Trial

Novavax Delays Signing Of Vaccine Supply Contract Due To Production Issues

EU

Reuters reporting US pharma company Novavax has informed the EU that it is set to delay the signing of a vaccine supply contract with the bloc due to production issues with its vaccine.

  • The firm currently has a contract with the UK gov't for 60mn doses to be produced at Stockton-on-Tees in the UK. It is unclear whether this contract will be met.
  • This seems to be different from the scenario involving AstraZeneca, where the contract was signed but then supply fell short. Here, Novavax seems to acknowledge that there are production issues initially, avoiding the prospect of signing a contract for more doses than it can produce.
  • The firm cites a shortage of raw materials as the reason for the production issues.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.